The Advisory Board Co. (NASDAQ:ABCO) CEO Robert W. Musslewhite sold 5,500 shares of the company’s stock in a transaction on Monday, October 10th. The stock was sold at an average price of $43.89, for a total transaction of $241,395.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

The Advisory Board Co. (NASDAQ:ABCO) opened at 43.76 on Thursday. The Advisory Board Co. has a one year low of $18.87 and a one year high of $54.83. The stock’s market capitalization is $1.76 billion. The stock’s 50 day moving average is $43.10 and its 200 day moving average is $37.20.

The Advisory Board (NASDAQ:ABCO) last issued its quarterly earnings results on Wednesday, July 27th. The company reported $0.47 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.34 by $0.13. The firm had revenue of $198.40 million for the quarter, compared to analysts’ expectations of $196.49 million. The Advisory Board had a positive return on equity of 11.59% and a negative net margin of 10.21%. The Advisory Board’s revenue was up 7.4% on a year-over-year basis. During the same quarter last year, the business posted $0.40 EPS. On average, equities analysts forecast that The Advisory Board Co. will post $1.86 EPS for the current year.

Insider Buying and Selling by Quarter for The Advisory Board (NASDAQ:ABCO)

A number of institutional investors have recently modified their holdings of ABCO. Confluence Investment Management LLC boosted its position in shares of The Advisory Board by 1,192.7% in the second quarter. Confluence Investment Management LLC now owns 614,292 shares of the company’s stock worth $21,740,000 after buying an additional 566,772 shares in the last quarter. Stoneridge Investment Partners LLC bought a new position in shares of The Advisory Board during the second quarter worth $2,287,000. Douglas Lane & Associates LLC boosted its position in shares of The Advisory Board by 31.6% in the second quarter. Douglas Lane & Associates LLC now owns 683,294 shares of the company’s stock worth $24,182,000 after buying an additional 164,025 shares in the last quarter. Bank of Montreal Can bought a new position in shares of The Advisory Board during the second quarter worth $8,706,000. Finally, Fox Run Management L.L.C. bought a new position in shares of The Advisory Board during the second quarter worth $297,000.

A number of research firms have recently weighed in on ABCO. Zacks Investment Research raised shares of The Advisory Board from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a research note on Wednesday, July 6th. Raymond James Financial Inc. cut shares of The Advisory Board from an “outperform” rating to a “market perform” rating in a research note on Tuesday, July 19th. Barclays PLC upped their price target on shares of The Advisory Board from $44.00 to $50.00 and gave the stock an “overweight” rating in a research note on Friday, September 30th. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and set a $49.00 price target (up from $45.00) on shares of The Advisory Board in a research note on Wednesday, September 28th. Finally, William Blair reaffirmed an “outperform” rating on shares of The Advisory Board in a research note on Tuesday, September 27th. Five research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $44.07.

The Advisory Board Company Profile

The Advisory Board Company is a provider of software and solutions to the healthcare and higher education industries. The Company’s healthcare programs address a range of clinical and business issues, including physician alignment and engagement, network management and growth strategy, value-based care and population health, revenue cycle, clinical operations and supply chain.

5 Day Chart for NASDAQ:ABCO

Receive News & Stock Ratings for The Advisory Board Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Advisory Board Co. and related stocks with our FREE daily email newsletter.